Struggling in R&D, GSK lines up an FDA pitch on COPD with mixed data
One of the few things that GlaxoSmithKline’s pharma R&D group got right in the last few years was mepolizumab, approved for severe asthma in 2015 and sold as Nucala. And now, with rivals looking to compete over market turf in its core respiratory field, investigators have mapped out a shot at an expansion into the COPD market for patients at high risk of exacerbations.
But hitting that goal will rely on shaky data, with plenty of holes in the evidence and a heavy reliance on a biomarker for disease severity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
